Patients & families
Challenge
Psoriasis
Psoriasis is a common inflammatory skin condition
involving 2-4% of the global population. It is clinically
characterized by erythematous and scaly plaques that
persist throughout life in variable severity and is in large
part caused by T-lymphocyte dysfunction.
Psoriasis is associated with an increased risk of developing co-
conditions, such as obesity, hypertension, diabetes, lymphoma, stroke
and psychological depraving traits like depression, anxiety and antisocial
behavior – all resulting in a substantial impact on the affected quality of
life. Pathology onset is an interaction between genetic, environmental
and immunological factors. Flares of Psoriasis can be triggered by local
stimuli (eg. scratching), systemic factors such as infections or medication,
or psychological factors like stress treatments across a versatile range of
indications
Facts and figures
Psoriasis is associated with an increased risk of developing co-conditions, such as obesity, hypertension, diabetes, lymphoma, stroke and psychological depraving traits like depression, anxiety and antisocial behavior – all resulting in a substantial impact on the affected quality of life. Pathology onset is an interaction between genetic, environmental and immunological factors.
Mild-to-Moderate
The US with acim quam ratem eos dis ma doluptatist, omnimintio cus eatem quias.
PDE4 inhibitor
Dermatology market and include
topical roflumilast cream
PDE4 Market and include
topical roflumilast cream
Moderate-to-servere
People in the US with acim quam
ratem eos dis ma doluptatist,
omnimintio cus eatem quias.
TNF-Q + 11-17
Plaque psoriasis and atopic
dermatitis
Acim quam ratem eos dis ma
doluptatist
Checkpoint-for Psoriasis
US with Acim quam ratem eos dis
ma doluptatist, omnimintio cus
eatem quias.
Keratinoc
Exerting anti-inflammatory effect
reducing psoriasis scale formation
PDE4 Market and include
topical roflumilast cream
